Strengthening International Partnerships, Expanding Global Opportunities
Rooted in China with a global reach, driving international expansion and operational excellence.
Approved in 60+
Countries, Covering Key
Global Markets
11 International GMP Certifications Including
7 PIC/S Members
Localized Operational
Network Built Via 12
Global Subsidiaries
Global Workforce
Empowered By Global Talent
Commercialized in
20+ Global Markets
Units Of Finished Insulin Products Sold In 2025
Full Value Chain Assurance · Global Fulfillment
Backed by large-scale in-house manufacturing and a stringent quality system, we deliver compliant and efficient solutions for global partners.
In-house Manufacturing Excellence · Scaled Capabilities
A modern manufacturing facility spanning 630,000 m², equipped with world-class production, testing, and real-time monitoring systems
Fully integrated in-house production of drug substance and finished products, large-scale stable production capacity, and high self-control over key links in the entire chain
Nearly 30 years of commercial manufacturing experience with mature, robust processes to ensure efficient and reliable product delivery
Full Value Chain Assurance · Global Fulfillment
Backed by large-scale in-house manufacturing and a stringent quality system, we deliver compliant and efficient solutions for global partners.
Compliant Logistics · Global Delivery
Closed-loop cold chain with precise temperature-controlled storage and transportation across multiple temperature ranges, with transportation solutions validated by regulatory authorities in multiple countries
Vetted compliant logistics partners with flexible, global transport capacity allocation
Continuous expansion of regional warehousing hubs to ensure reliable supply
Full Value Chain Assurance · Global Fulfillment
Backed by large-scale in-house manufacturing and a stringent quality system, we deliver compliant and efficient solutions for global partners.
Quality First · Science Driven
Operating a global quality management system aligned with applicable NMPA, EU, and US FDA GMP requirements, as well as ICH Q10 guidelines, covering the entire product lifecycle from drug development to commercial manufacturing and supporting continuous improvement
Focused on Core Therapeutic Areas · Global Cooperation
Focusing on metabolic diseases and other key therapeutic areas, we collaborate with global partners to accelerate the commercialization of established products and the development of innovative medicines, bringing high-quality healthcare solutions to patients worldwide.
Metabolic Therapeutic Area
Focused on global therapeutic needs in diabetes, obesity, and other metabolic disease areas, we are developing a diversified pipeline to build a comprehensive therapeutic product portfolio addressing diverse patient needs.
Other Therapeutic Areas
Driven by unmet clinical needs, we continuously expand our innovative pipeline and therapeutic solutions to unlock new possibilities across diverse disease areas.
Diverse Models · Open for Mutual Success
Flexible, tailored partnership models designed to maximize global value creation
Product Commercialization and Distribution Partnership
Leveraging a comprehensive insulin portfolio and a robust global compliance system to expand international partnerships for commercialization and distribution.
Innovative Pipeline Licensing and Co-development
We are committed to out-licensing innovative assets and building long-term strategic partnerships worldwide. By combining complementary strengths in innovative pipelines, advanced R&D platforms, local market expertise, and clinical development and commercialization capabilities, we aim to accelerate global clinical trials and market launches, ultimately expanding access to innovative medicines worldwide.
Technology Transfer and Localized Manufacturing
Providing localized solutions ranging from drug substance supply to technology transfer, strengthening regional manufacturing capabilities and building resilient supply chains through close technical collaboration.
Tech Transfer Projects Executed
with Partnerships
of Tech Transfer Expertise
Pharmaceutical Packaging & Excipients Partnerships
Providing one-stop solutions for primary packaging components and pharmaceutical excipients, with flexible sourcing options for essential materials and components, including stoppers, aluminum seals, pen injection devices, and needles, tailored to partner needs.
Leveraging a robust drug substance supply infrastructure, we support bundled procurement of drug substances and packaging materials. This streamlines supply chain coordination for pharmaceutical partners, ensuring reliable end-to-end supply while reducing procurement and administrative costs.
Sailing Overseas, Growing Worldwide
Broadening access to healthcare worldwide
First Overseas Commercialization
Achieved initial overseas commercialization of insulin glargine, marking the inception of our global presence
First Overseas Subsidiary
Established a wholly-owned subsidiary in New Jersey, USA, driving international trade and overseas market expansion
Strategic Partnership with Sandoz
Partnered with global pharma leader Sandoz for the commercialization of insulin products, jointly expanding into US and European markets
Inaugural Year of New Drug Business Development
In 2025, Bofanglutide secured licensing partnerships across Latin America, India, South Korea, and Europe, marking a major milestone in Gan & Lee’s global expansion
The Menarini agreement covers 39 European countries and regions, with a €62 million upfront payment and a total potential deal value of up to €726 million, setting a new company record for out-licensing
EU Marketing Authorization
Successively obtained EU marketing authorizations for insulin glargine, insulin aspart, and insulin lispro, marking a historic breakthrough of the China-developed third-generation insulin analog portfolio into the highly-regulated European market
Global Updates
Gan & Lee Meets with Türkiye’s Deputy Minister of Health to Discuss Biopharmaceutical Cooperation
On October 15, 2026, Du Kai, Executive Vice President and Chief Commercial Officer (EVP & CCO) of Gan & Lee Pharmaceuticals ("Gan & Lee," stock code: 603087.SH), alongside the company's international business team, held a meeting with Türkiye's Deputy Minister of Health, Assoc. Prof. Şuayıp Birinci, and other officials in Ankara. The talks centered on cooperation on innovative medicines, reliable long-term insulin supply, and the development of local manufacturing capabilities. The meeting aimed to advance Gan & Lee's long-term strategic cooperation in Türkiye, expand access to therapies for metabolic diseases, and bolster supply security.
Read MoreGan & Lee’s Insulin Glargine Products Approved in El Salvador
Recently, Gan & Lee Pharmaceuticals ("Gan & Lee," stock code: 603087.SH) has achieved another milestone in its international expansion. The company's independently developed insulin glargine injection in both cartridges and prefilled pens has received approval from El Salvador's Superintendencia de Regulación Sanitaria (SRS). This marks another important registration milestone in Central America, following the approvals of the company's insulin glargine products in Honduras.
Read MoreGan & Lee’s Insulin Aspart Approved in Ethiopia: Two Core Insulin Products Approved in the Country This Year
Recently, Gan & Lee Pharmaceuticals ("Gan & Lee," stock code: 603087.SH) announced that its insulin aspart injection, manufactured by the company with Gan & Lee serving as the marketing authorization holder (MAH), received registration approval from the Ethiopian Food and Drug Authority (EFDA). It is the first insulin aspart biosimilar approved in Ethiopia. Following the clearance of its insulin glargine injection by EFDA in January 2026, Gan & Lee has secured approvals for two core insulin products in the country within a single year.
Read MoreEmpowering Global Partnerships, Building a Healthier Future
Guided by "Science and Excellence," we advance proprietary innovation and unite global capabilities to explore new frontiers in medicine, contributing sustainable long-term value to global health.
Contact Us